Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approach

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 7, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how the characteristics of tumors in women with endometrial carcinoma (a type of cancer in the uterus) can affect the choice of surgical treatment. Researchers want to see if selecting surgical routes based on these tumor characteristics can make the surgery safer in the short term and improve long-term outcomes for patients. They aim to develop a new system to help doctors make better decisions when treating women with this cancer, filling in gaps in current research.

To participate in this study, women aged 40 to 80 who have been diagnosed with endometrial carcinoma through a biopsy may be eligible. Key requirements include having no significant health issues with the liver or kidneys, being in good physical shape, and not having had prior cancer treatments. Participants will undergo surgery based on their tumor’s specific features and will be closely monitored throughout the study. This research represents an important step toward personalized treatment for endometrial carcinoma, making sure that patients receive the most appropriate care based on their unique tumor profiles.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged 40-80 years.
• • Preoperative hysteroscopic biopsy pathology is endometrial carcinoma, preoperative imaging evaluation of tumor limited to uterine or extrauterine metastasis limited to pelvic or para-aortic lymph nodes.
• • No liver and kidney function abnormalities and bone marrow suppression before surgery.
• • ECOG score 0 points.
• • Subjects voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with follow-up.
• • Molecular testing has confirmed that the participant does not have high mutational burden characteristics (including POLE mutations, MSI-H, homologous recombinant repair pathway mutations).
• Exclusion Criteria:
• • Preoperative adjuvant therapy.
• • Have contraindications to chemoradiotherapy and cannot receive postoperative adjuvant chemoradiotherapy.
• • Previous history of other malignant tumors or other malignant tumors at the same time.
• • Laparoscopic surgery transferred to open surgery for special reasons.
• • unable or unwilling to comply with the requirements of the study.